Stagg, HR, Bothamley, GH, Davidson, JA, Kunst, H, Lalor, MK, Lipman, MC, Loutet, MG, Lozewicz, S, Mohiyuddin, T, Abbara, A, Alexander, E, Booth, H, Creer, DD, Harris, RJ, Kon, OM, Loebinger, MR, McHugh, TD, Milburn, HJ, Palchaudhuri, P, Phillips, PPJ, Schmok, E, Taylor, L, Abubakar, I & on behalf of the London INH-R TB study group 2019, ' Fluoroquinolones and isoniazid resistant TB: implications for the 2018 WHO guidance ', European Respiratory Journal . https://doi.org/10.1183/13993003.00982-2019
Nahid, Payam; Phillips, PPJ; Dooley, KE; Gillespie, SH; Heinrich, N; Stout, JE; et al.(2016). A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/8cv271t5